BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Tempus AI Stock Rises on FDA Clearance for RNA-Based Diagnostic Tool
Tempus AI Stock Rises on FDA Clearance for RNA-Based Diagnostic Tool
23
3
BTCCSquare news:
Tempus AI shares gained in premarket trading following FDA clearance for its Tempus xR IVD device, a breakthrough in tumor analysis. The RNA-sequencing tool identifies molecular pathways in cancer progression, enabling targeted patient selection for clinical trials.
Monday's trading saw TEM hit an all-time high of $97.39 before closing down 2.7%. The premarket rebound suggests sustained investor confidence in the company's data-driven oncology solutions. Tempus' technology positions it as a key partner for biopharma firms seeking efficient trial methodologies.
By:
